Literature DB >> 10550590

Pineal and nonpineal supratentorial primitive neuroectodermal tumors.

R I Jakacki1.   

Abstract

Pineal region supratentorial primitive neuroectodermal tumors (SPNETs; pineoblastomas) and nonpineal SPNETs are rare tumors that historically have carried a very poor prognosis. With multimodality therapy, including maximal surgical resection, craniospinal radiation therapy and chemotherapy, the survival for patients with pineal PNETs has significantly improved. Chemotherapy alone, at least in conventional doses, appears to be insufficient treatment for younger children with pineoblastomas, in whom there is almost universal rapid tumor progression and death. Survival of patients with nonpineal SPNETs remains in the order of 30-35% despite multimodality therapy. Unlike those with pineal SPNETs, a significant percentage of infants with nonpineal SPNETs who undergo gross total surgical resection followed by chemotherapy will be long-term survivors. This article gives an overview of the natural history, prognostic factors and treatment of both pineal and nonpineal SPNETs.

Entities:  

Mesh:

Year:  1999        PMID: 10550590     DOI: 10.1007/s003810050547

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  9 in total

1.  Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91.

Authors:  Bernward G Hinkes; Katja von Hoff; Frank Deinlein; Monika Warmuth-Metz; Niels Soerensen; Beate Timmermann; Uwe Mittler; Christian Urban; Udo Bode; Torsten Pietsch; Paul G Schlegel; Rolf D Kortmann; Joachim Kuehl; Stefan Rutkowski
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

2.  Congenital pineoblastoma and parameningeal rhabdomyosarcoma: concurrent two embryonal tumors in a young infant.

Authors:  Funda Corapçíoğlu; M Memet Ozek; Aydin Sav; Deniz Uren
Journal:  Childs Nerv Syst       Date:  2005-11-09       Impact factor: 1.475

3.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.

Authors:  Michel De Vos; Bruce E Hayward; Susan Picton; Eamonn Sheridan; David T Bonthron
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

4.  Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy.

Authors:  Stephen W Gilheeney; Ali Saad; Susan Chi; Christopher Turner; Nicole J Ullrich; Liliana Goumnerova; R Michael Scott; Karen Marcus; Leslie Lehman; Umberto De Girolami; Mark W Kieran
Journal:  J Neurooncol       Date:  2008-04-16       Impact factor: 4.130

5.  Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report.

Authors:  Donna L Johnston; Daniel L Keene; Lucie Lafay-Cousin; Paul Steinbok; Lillian Sung; Anne-Sophie Carret; Bruce Crooks; Douglas Strother; Beverly Wilson; Isaac Odame; David D Eisenstat; Chris Mpofu; Shayna Zelcer; Annie Huang; Eric Bouffet
Journal:  J Neurooncol       Date:  2007-07-10       Impact factor: 4.130

Review 6.  Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors.

Authors:  Patrick Sin-Chan; Bryan K Li; Ben Ho; Adriana Fonseca; Annie Huang
Journal:  Curr Oncol Rep       Date:  2018-07-11       Impact factor: 5.075

7.  Endoscopic options in management of posterior third ventricular tumors.

Authors:  S V Roopesh Kumar; Aaron Mohanty; Vani Santosh; Satyanarayana Satish; B Indira Devi; Shanti Shankar Praharaj; Sastry V R Kolluri
Journal:  Childs Nerv Syst       Date:  2007-05-31       Impact factor: 1.475

8.  Supratentorial primitive neuroectodermal tumor presenting with intracranial hemorrhage in adult.

Authors:  Bashar Abuzayed; Wiam Khreisat; William Maaiah; Saoud Agailat
Journal:  J Neurosci Rural Pract       Date:  2014-04

9.  Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.

Authors:  Seo Hee Choi; Se Hoon Kim; Kyu-Won Shim; Jung Woo Han; Junjeong Choi; Dong-Seok Kim; Chuhl Joo Lyu; Jun Won Kim; Chang-Ok Suh; Jaeho Cho
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.